# Daily Market Review

Market closed positive

**15-Nov-2026**

## DSEX WENT UP BY 15.7 POINTS

Market closed positive today with increase in turnover.


Broad index DSEX went up by 15.7 points.

Jute, Mutual Fund and Textile are the top three sectors that closed positive today while L. Insurance, IT and G. Insurance are the top three sectors that closed negative today.


Turnover increased by 5.8% to BDT 7,392mn (USD 60mn).

Textile sector dominated the turnover chart covering 22.8% of the total turnover.


### Intraday Performance of DSEX





### Sector Return




### Sector P/E




### 52 Week Daily Turnover & DSEX




### Index

| Particulars | Value | Δ Points | Daily Δ % | Dec'25 Value | YTD Δ % |
|---|---|---|---|---|---|
| DSEX | 5,460.56 | 15.7 | 0.29% | 4,865.34 | 12.23% |
| DS30 | 2,078.11 | 18.7 | 0.91% | 1,853.54 | 12.12% |
| DSES | 1,064.86 | 7.6 | 0.71% | 1,000.72 | 6.41% |
| S&P 500 | 7,561.67 | (30.7) | -0.40% | 6,845.50 | 10.46% |
| Nikkei 225 | 61,142.35 | 323.0 | 0.53% | 50,339.48 | 21.46% |
| FTSE 100 | 10,902.56 | 39.5 | 0.36% | 9,931.38 | 9.78% |

### Market Statistics

| Particulars | Today | Last Day | Daily Δ | Daily Δ % | 60 Day MA |
|---|---|---|---|---|---|
| Turnover (BDT mn) | 7,392 | 6,990 | 402 | 5.75% | 5,836 |
| Turnover (USD mn) | 60 | 57 | 3 | 5.75% | 48 |
| Volume (mn) | 243 | 224 | 18 | 8.20% | 202 |
| Market Cap (BDT bn) | 6,709 | 6,699 | 10 | 0.15% | |
| Market Cap (USD bn) | 55 | 55 | 0 | 0.15% | |
| Market P/E (x) | 8.3 | | | | |

| Particulars | Gainer | Loser | Unchanged |
|---|---|---|---|
| Market Breadth | 133 | 210 | 37 |

### Sector Statistics

| Sector | Market Cap (BDTmn) | % of total Market Cap | Sector Return | Turnover (BDTmn) | % of total Turnover |
|---|---|---|---|---|---|
| Bank | 731,875 | 21.77% | 1.0% | 598.7 | 8.10% |
| Pharma | 569,550 | 16.94% | 0.7% | 1,008.4 | 13.64% |
| Telecom | 489,188 | 14.55% | 0.1% | 56.4 | 0.76% |
| Fuel & Power | 295,582 | 8.79% | 0.1% | 1,184.5 | 16.02% |
| Engineering | 280,268 | 8.34% | -0.4% | 391.6 | 5.30% |
| Food & Allied | 195,019 | 5.80% | 0.0% | 387.8 | 5.25% |
| Textile | 150,501 | 4.48% | 1.6% | 1,682.1 | 22.75% |
| Misc | 137,128 | 4.08% | -0.7% | 235.4 | 3.18% |
| G. Insurance | 119,242 | 3.55% | -1.0% | 589.9 | 7.98% |
| NBFI | 95,035 | 2.83% | -0.9% | 183.3 | 2.48% |
| Cement | 85,810 | 2.55% | -0.3% | 49.3 | 0.67% |
| L. Insurance | 46,028 | 1.37% | -1.4% | 73.2 | 0.99% |
| Travel & Leisure | 33,300 | 0.99% | 0.8% | 30.2 | 0.41% |
| IT | 29,953 | 0.89% | -1.3% | 128.2 | 1.73% |
| Mutual Fund | 29,626 | 0.88% | 2.0% | 303.8 | 4.11% |
| Services & Real Estate | 25,788 | 0.77% | 0.0% | 176.0 | 2.38% |
| Tannery | 23,246 | 0.69% | 0.3% | 47.2 | 0.64% |
| Ceramics | 20,272 | 0.60% | 1.5% | 108.4 | 1.47% |

### Top Turnover

| Ticker | Close Price (BDT) | Daily Δ % | Turnover (BDTmn) | Volume (mn) | P/E (x) |
|---|---|---|---|---|---|
| SAIHAMTEX | 53.50 | 3.88% | 333.21 | 6.44 | 162.12 |
| SPCL | 64.40 | -3.45% | 269.55 | 4.14 | 10.59 |
| BPPL | 23.50 | 6.82% | 266.91 | 11.32 | 5.65 |
| DOREENPWR | 38.90 | -3.23% | 212.67 | 5.39 | 7.15 |
| SQURPHARMA | 219.70 | 0.41% | 202.04 | 0.92 | 6.94 |

### Top Gainers

| Ticker | Close Price (BDT) | Daily Δ % | Turnover (BDTmn) | Volume (mn) | P/E (x) |
|---|---|---|---|---|---|
| MATINSPINN | 123.50 | 10.00% | 147.59 | 1.24 | 15.87 |
| WATACHEM | 140.00 | 9.98% | 7.20 | 0.05 | 29.98 |
| ISLAMIBANK | 23.40 | 9.86% | 6.44 | 0.28 | n/a |
| GREENDELMF | 4.50 | 9.76% | 14.90 | 3.32 | n/a |
| SKTRIMS | 14.00 | 9.38% | 6.09 | 0.44 | n/a |

### Top Losers

| Ticker | Close Price (BDT) | Daily Δ % | Turnover (BDTmn) | Volume (mn) | P/E (x) |
|---|---|---|---|---|---|
| SBACBANK | 5.60 | -9.68% | 7.38 | 1.28 | 93.33 |
| GSPFINANCE | 3.20 | -8.57% | 1.37 | 0.42 | n/a |
| ACIFORMULA | 129.00 | -7.19% | 26.20 | 0.20 | 20.38 |
| KPCL | 10.60 | -7.02% | 10.60 | 0.99 | n/a |
| DELTASPINN | 6.90 | -6.76% | 8.88 | 1.28 | n/a |

***Please see penultimate page for additional important disclosures:*** *UCB Stock Brokerage Ltd. ("UCB") is a foreign broker-dealer unregistered in the USA. UCB research is prepared by analysts who are not registered in the USA. UCB research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Marco Polo Securities Inc., an SEC registered and FINRA-member broker-dealer.*

# Daily Market Review

Market closed positive

**15-Nov-2026**

**BXPHARMA**

**Appointment of Managing Director**

The company has informed that the Board of Directors in its meeting held on November 12, 2026 has approved the appointment of Mr. S. M. Rabbur Reza as a Director and Managing Director of the company with immediate effect.

**BXPHARMA**

**Board Approves Formation of Wholly Owned Subsidiary**

The company has informed that the Board of Directors, in its meeting held on 12 November 2026, approved the incorporation of a new company under the proposed name Beximco Pharma Nutraceuticals Ltd., as a wholly owned subsidiary of the Company. The proposed subsidiary will engage in the manufacturing and marketing of herbal medicinal products as part of Beximco Pharma's strategy to diversify its product portfolio and expand its presence in the healthcare market. The proposed company will have an authorized share capital of Tk. 100 crore, divided into 10 crore ordinary shares of Tk. 10 each, and an initial paid-up share capital of Tk. 10 crore, to be fully subscribed by Beximco Pharmaceuticals PLC. The incorporation of the subsidiary and commencement of its operations will be subject to obtaining the necessary statutory and regulatory approvals. The Company does not anticipate any material impact on its financial performance in the immediate or medium term arising from this initiative.

**BXPHARMA**

**Q1 Financials**

Consolidated EPS was Tk. 5.72 for July-September 2026 as against Tk. 5.30 for July-September 2025. Consolidated NOCFPS was Tk. 8.06 for July-September 2026 as against Tk. 6.14 for July-September 2025. Consolidated NAV per share was Tk. 144.90 as on September 30, 2026 and Tk. 124.34 as on September 30, 2025.

**ACMELAB**

**Q1 Financials**

EPS was Tk. 3.40 for July-September 2026 as against Tk. 3.01 for July-September 2025. NOCFPS was Tk. 5.81 for July-September 2026 as against Tk. 7.07 (restated) for July-September 2025. NAV per share was Tk. 142.76 as on September 30, 2026 and Tk. 139.37 as on June 30, 2026.

**UPGDCL**

**Q1 Financials**

Consolidated EPS was Tk. 4.67 for July-September 2026 as against Tk. 4.94 for July-September 2025. Consolidated NOCFPS was Tk. 17.46 for July-September 2026 as against Tk. 6.62 for July-September 2025. Consolidated NAV per share was Tk. 88.00 as on September 30, 2026 and Tk. 83.33 as on June 30, 2026. Reasons for deviation: Consolidated NOCFPS increased significantly, primarily driven by substantial collections from trade receivables, which resulted in higher net operating cash inflows.

**Block Trade**

| Ticker | Max Price (BDT) | Min Price (BDT) | No. of Trades | Volume | Value (BDTmn) |
|---|---|---|---|---|---|
| ADVENT | 13.9 | 13.9 | 1 | 200000 | 2.78 |
| APEXSPINN | 385 | 385 | 4 | 100000 | 38.5 |
| ASIATICLAB | 104.5 | 104.5 | 1 | 5000 | 0.523 |
| BRACBANK | 66.6 | 66.3 | 3 | 500000 | 33.21 |
| CITYGENINS | 138.1 | 138 | 5 | 277900 | 38.377 |
| DOMINAGE | 65.1 | 63.4 | 2 | 50000 | 3.213 |
| DOREENPWR | 43 | 40.3 | 2 | 88440 | 3.767 |
| ETL | 15 | 14.6 | 4 | 580000 | 8.625 |
| FEKDIL | 20.8 | 20.7 | 2 | 240000 | 4.988 |
| FINEFOODS | 420 | 410 | 2 | 9892 | 4.103 |
| GQBALLPEN | 600 | 579 | 3 | 10728 | 6.401 |
| IFIC | 5 | 5 | 1 | 1500000 | 7.5 |
| INTRACO | 24 | 24 | 1 | 65000 | 1.56 |
| KARNAPHULI | 53 | 53 | 1 | 18000 | 0.954 |
| KDSALTD | 46 | 46 | 1 | 30000 | 1.38 |
| MALEKSPIN | 48 | 48 | 3 | 195100 | 9.365 |
| MJLBD | 81.5 | 81.5 | 1 | 10000 | 0.815 |
| NAVANAPHAR | 64.6 | 64.6 | 1 | 8300 | 0.536 |
| NITOLINS | 58.6 | 58.6 | 1 | 21500 | 1.26 |
| ORIONPHARM | 27.1 | 27.1 | 1 | 251001 | 6.802 |
| PRAGATIINS | 71.4 | 71.4 | 1 | 10500 | 0.75 |
| PRIMEBANK | 28.9 | 28.9 | 1 | 1000000 | 28.9 |
| PTL | 82 | 80.9 | 5 | 51218 | 4.172 |
| RDFOOD | 24.4 | 24.4 | 1 | 25000 | 0.61 |
| RUNNERAUTO | 53.5 | 52.9 | 2 | 18798 | 1 |
| SAFKOSPINN | 23 | 23 | 1 | 29748 | 0.684 |
| SAIHAMTEX | 51 | 49 | 11 | 1543840 | 77.056 |
| SEAPEARL | 36.6 | 36.6 | 1 | 16000 | 0.586 |
| SIPLC | 135 | 135 | 5 | 525300 | 70.916 |
| SONARGAON | 125.3 | 120 | 4 | 154200 | 18.952 |
| UNIONCAP | 5.8 | 5.8 | 1 | 111000 | 0.644 |
| UNITEDFIN | 18.1 | 18.1 | 3 | 104817 | 1.897 |

# Disclaimer

**For U.S. persons only:** This research report is a product of UCB Stock Brokerage Ltd. ("UCB"), a company authorized to engage in securities activities in Bangladesh, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution by only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, UCB has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UCB Stock Brokerage Limited (UCB) with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UCB and UCB accepts no liability whatsoever for the actions of third parties in this respect.

## EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the % of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

| Recommendation Type | Holding period (if not otherwise mentioned) | Absolute Return Potential |
|---|---|---|
| Buy | 12 Months | More than +15% |
| Neutral/ Hold | 12 Months | Between -5% and +15% |
| Underweight | 12 Months | Less than -5% |

## ANALYST CERTIFICATION

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

*It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.*

# Contact Us

### Research Team

| | | | |
|---|---|---|---|
| Md. Sakib Chowdhury, CFA | Head of Research | chowdhury.md.sakib@ucbstock.com.bd | +880 1713 205 698 |
| Anik Mahmood Ibne Anwar, CFA | Deputy Head of Research | anik.mahmood@ucbstock.com.bd | +880 1701 205 074 |
| Fahmid Islam Sadhin | Research Associate | fahmid.islam@ucbstock.com.bd | +880 1325 086 738 |
| Numair M N Ahmmed | Research Associate | ahmmed.numair@ucbstock.com.bd | +880 1324 719 484 |
| Kazi Rafi Hasan | Research Associate | kazi.rafi.hasan@ucbstock.com.bd | +880 1335 212 250 |
| Md. Redwan Bin Rahman | Research Associate | redwan.bin.rahman@ucbstock.com.bd | +880 1712 733 003 |

## Office Premises

### Head Office

**Gulshan**
Bulus Center
+880 2955 8481

### Extensions of Head Office

| | | | | |
|---|---|---|---|---|
| **Dilkusha**<br>+880 1701 205 090 | **Dilkusha (Sun Moon Tower)**<br>+880 1701 205 000 | **Dhanmondi**<br>+880 1713 205 703 | **Nikunja**<br>+880 1701 205 013 | **Mohammadpur**<br>+880 1324 243 212 |
| **Bashundhara**<br>+880 1718 106 217 | **Mirpur-1**<br>+880 1713 205 723 | **Mirpur-12**<br>+880 1911 197 188 | **Banasree**<br>+880 1701 205 075 | **Uttara**<br>+880 1913 128 156 |

### Branch Offices

| | |
|---|---|
| **Chattogram**<br>+880 1701 205 038 | **Sylhet**<br>+880 1713 205 760 |

### Digital Booths

| | | | | |
|---|---|---|---|---|
| **Khulna**<br>+880 1717 411 466 | **Barishal**<br>+880 1713 205 762 | **Cumilla**<br>+880 1324 243 163 | **Jashore**<br>+880 1324 243 203 | **Gazipur**<br>+880 1324 243 165 |
| **Feni**<br>+880 1324 243 210 | **Khatungonj**<br>+880 1713 205 742 | **Chawkbazar**<br>+880 1817 206 965 | **Madhobdi**<br>+880 1324 243 156 | |
| **Narayangonj**<br>+880 1324 243 207 | **Agrabad**<br>+880 1324 243 198 | | | |